TWST
Twist Bioscience CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 11 Piper Sandler initiates
- Jun 15 Canaccord Genuity initiates
- Jun 30 ▲ 6 funds open new positions (13F)
- Jul 6 ▼ Evercore ISI Group downgrades
- Sep 9 2 analysts initiate
- Sep 17 to Oct 9 ▼ 7 days of insider sells: $78.1M by 6 insiders, avg $165.29
- Oct 8 Jefferies initiates
- Oct 13 ▼ Six Twist Bioscience insiders, including the CEO, President/COO, and…
- Oct 23 ▼ 1 insider sell $302.2K at $134.59
- Nov 3 ▼ 5 insiders sell $1.3M at $135.40
- Nov 12 ▲ Twist Bioscience reported fiscal Q4 2026 revenue of $126.6M (+28% Yo…
- Nov 12 ▲ Earnings: TWST Q4 2026 Earnings: EPS $-0.32 (+14.6% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $79.6M.
- InstitutionsBULLISH
Q2 2026: 49 added (6 new), 30 trimmed or exited. Largest new: Fil $66.0M, Marshall Wace $40.8M.
- AnalystsBULLISH
14 of 19 rate it Buy or better.
- Short sellersSTEADY
Short interest −3.6% to 9.84M shares. 4.3 days to cover, ≈14.8% of shares.
- TrendDOWNTREND
30% below its 50-day average.
- SocialQUIET
Crowd 64° (warm) this week from 3 mentions: 2 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $483.8M |
| ARK Investment Management LLC | TRIM | $468.1M |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $373.9M |
| EdgePoint Investment Group Inc. | TRIM | $259.4M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | TRIM | $223.7M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | ADD | $219.8M |
| MORGAN STANLEY | DOUBLED | $122.4M |
| D. E. Shaw & Co., Inc. | DOUBLED | $122.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 13, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 13, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 13, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 13, 2026 | Baird MAINTAIN | Outperform |
| Oct 13, 2026 | TD Cowen MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
WERNER ROBERT F. Chief Accounting Officer Nov 3, 2026 | SELL | $20.0K |
Cho Dennis See Remarks Nov 3, 2026 | SELL | $128.5K |
Finn Patrick John President and COO Nov 3, 2026 | SELL | $347.3K |
Leproust Emily M. Chief Executive Officer Nov 3, 2026 | SELL | $619.2K |
Green Paula SVP of Human Resources Nov 3, 2026 | SELL | $136.3K |
Finn Patrick John President and COO Oct 23, 2026 | SELL | $302.2K |
Laponis Adam Chief Financial Officer Oct 9, 2026 | SELL | $384.8K |
Leproust Emily M. Chief Executive Officer Oct 5, 2026 | SELL | $88.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
44 filings · 3 bullish · 9 bearish · 32 neutral- NEUTRAL 144Nov 16, 2026
Paula Green, an officer of Twist Bioscience, filed a Form 144 notice to sell 4,281 shares of common stock valued at approximately $443,890, with the sale expected on or after November 16, 2026. The shares were acquired through restricted stock vesting on November 12, 2026, and the filing is a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing beneficial ownership of 6,084,637 shares of Twist Bioscience Corp, representing 9.2% of shares outstanding as of September 30, 2026. This is a routine passive stake update by an investment adviser; the stake increased from the prior…
🔒 Fresh report (last 24h), subscribers only
- BULLISH 8-KNov 12, 2026
Twist Bioscience reported fiscal Q4 2026 revenue of $126.6M (+28% YoY), above the $123.6M…
Monitor Q1 FY2027 results for continued sequential growth and margin expansion. The company's ability to sustain adjusted EBITDA profitability and execute on its $75M capex plan will be key. AI drug…
- NEUTRAL SC 13G/ANov 12, 2026
Artisan Partners Limited Partnership filed an amended Schedule 13G disclosing beneficial ownership…
Monitor for any future conversion to a Schedule 13D if Artisan's intent changes from passive to activist, though current filing certifies passive intent.
All TWST filing & press-release reports (44)
- 144 reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 12, 2026
- SC 13G/A reportNov 12, 2026
- SC 13G reportNov 10, 2026
- CLUSTER reportNov 5, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- 144 reportNov 3, 2026
- 144 reportNov 3, 2026
- 144 reportNov 3, 2026
- 144 reportNov 3, 2026
- CLUSTER reportOct 13, 2026
- 144 reportOct 9, 2026
- CLUSTER reportOct 5, 2026
- CLUSTER reportSep 25, 2026
- CLUSTER reportSep 23, 2026
- CLUSTER reportSep 10, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 14, 2026
- 144 reportAug 12, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 7, 2026
- 144 reportAug 7, 2026
- CLUSTER reportAug 5, 2026
- 8-K reportAug 3, 2026
- CLUSTER reportJun 24, 2026
- S-3ASR reportJun 18, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportJun 1, 2026
- CLUSTER reportMay 28, 2026
- CLUSTER reportMay 26, 2026
- 8-K reportMay 4, 2026
- CLUSTER reportApr 17, 2026
- CLUSTER reportMar 17, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026